MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Metabolon Advances Metabolomics Innovation with New SmartPanel™ Portfolio

inCompany News

The new biological pathway focus, paired with a proprietary pathway visualization tool, gives users a new way to interpret the metabolome.

MORRISVILLE, N.C. – October 27, 2021 – As part of its continued commitment to developing innovative tools and solutions that advance the understanding of human health and the life sciences, Metabolon, Inc., has launched the first offering from its new SmartPanel™ portfolio. SmartPanel solutions provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations.

Metabolon’s Microbiome SmartPanel demystifies the gut microbiome by zeroing in on biologically relevant microbial and host-derived metabolites, along with xenobiotic molecules, to reveal deep insight into microbiome function and its impact on host health. The proprietary Heliogram™ visualization tool allows users to explore 13 microbiome pathways for rapid connectivity to the impact of therapeutic interventions on the host microbiome. In addition, the on-demand access to Metabolon’s comprehensive pathway knowledge base gives seamless access to expertly curated, microbiome-relevant disease associations and biological themes.

“The metabolome offers a window into human biology, providing insights on the human body’s response to chemicals and revealing the biological fingerprint to enable data-driven decisions. This ‘omics technology also reveals the potential utility of drugs for specific indications,” says Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer, Metabolon. “The metabolome represents the end-point product of complex network biology. Metabolomics is an untapped, underappreciated biological resource. It can significantly contribute to the evolution of healthcare system technologies because the insights revealed influence almost every aspect of health, treatment of diseases, and health outcomes.”

“Metabolomics is a potent and incredibly powerful tool for drug developers because it provides real-time, functional insight of the phenotype,” says Rohan Hastie, Ph.D., President and CEO, Metabolon. “But we’ve also heard from our commercial clients that the sheer volume of data we provide from our industry-leading untargeted platform can be overwhelming. Our SmartPanel solution offers a focused view of biologically relevant metabolites in a dynamic format that allows researchers to explore comparisons and associations of data most relevant to their unique study.”

Metabolon’s Microbiome SmartPanel is ideal for discovering microbiota-related biomarkers and for elucidating the mechanism of action of therapeutics and it may also inform on dose selection and efficacy. The company has plans to unveil additional SmartPanel offerings in the coming months. In addition, the company is developing novel methods for a number of new Targeted Assays, which can be validated up to Good Clinical Practice (GCP) requirements if needed.

“This is the beginning of a robust portfolio of new dynamic and easy-to-understand metabolomics solutions,” continues Hastie. “Our belief is that by making metabolomics solutions more accessible for use by the broader market, we can make it possible for more drug developers to leverage the power of metabolomics to develop new therapies to improve patient care.”

About Metabolon 
Metabolon, Inc., is the global leader in metabolomics, with a mission to deliver metabolomics data and insights that expand and accelerate the impact of life sciences research in all its applications. Over 20 years, 10,000+ projects, 2,000+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific technology and bioinformatics techniques. Our Precision Metabolomics™ Platform has enabled the development of the world’s largest proprietary metabolomics reference library. Our industry-leading data and translational science experts help our clients address some of the most challenging and pressing questions in the life sciences, accelerating research, and development success. The company offers scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

Media Inquiries:

Elizabeth Romero, Manager, Marketing Communications, Metabolon, Inc., Mobile: 984-243-1413, [email protected]

Back to News & Events
  • Event: Microbiome R&D & Business Collaboration Forum: Europe
    Previous PostEvent: Microbiome R&D & Business Collaboration Forum: Europe
  • Next PostWebinar: Meet Smart: Metabolon and DNA Genotek unveil new microbiome research innovations that will change how we view the gut microbiota
    Event: Microbiome R&D & Business Collaboration Forum: Europe

Related Posts

Event: Precision Medicine World Conference (PMWC)
Events

Event: Precision Medicine World Conference (PMWC)

Webinar: Integrated Multiomic Analysis for Disease
Events

Webinar: Integrated Multiomic Analysis for Disease

Metabolomics in drug discovery: The missing piece for multi-omics data
Events

Metabolomics in drug discovery: The missing piece for multi-omics data

How Metabolomics Can Raise the Bar in Drug Development
Drug Development Working with Metabolon

How Metabolomics Can Raise the Bar in Drug Development

Metabolon Announces Chief Financial Officer Transition
Company News

Metabolon Announces Chief Financial Officer Transition

Lunch and Learn: Applications of Metabolomics in Microbiome Research
Events

Lunch and Learn: Applications of Metabolomics in Microbiome Research

Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen
Company News

Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen

Overcoming the Limitations of Mass Spectrometry Across Datasets
Blog Capabilities Working with Metabolon

Overcoming the Limitations of Mass Spectrometry Across Datasets

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes
Company News

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH
Biomarkers Drug Development

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in
Copy